Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Company Overview - Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3) [2] - The AP3 platform identifies patients whose tumors are predicted to be sensitive to specific medicines by measuring compound-specific effects on tumor cell protein signaling networks and drug-induced resistance mechanisms [2] Key Developments - Acrivon is advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial across multiple tumor types [2] - The FDA has granted Fast Track designation for ACR-368 as monotherapy for patients with platinum-resistant ovarian or endometrial cancer based on OncoSignature-predicted sensitivity [2] - ACR-368's OncoSignature assay has received Breakthrough Device designation from the FDA for identifying ovarian cancer patients who may benefit from ACR-368 treatment [2] Upcoming Events - The company's president and CEO, Peter Blume-Jensen, will present an overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 [1]